Abstract:Inactivation of p53 is present in almost every tumor, and hence, p53-reactivation strategies are an important aspect of cancer therapy. Common mechanisms for p53 loss in cancer include expression of p53-negative regulators such as MDM2, which mediate the degradation of wildtype p53 (p53α), and inactivating mutations in the TP53 gene. Currently, approaches to overcome p53 deficiency in these cancers are limited. Here, using non-small cell lung cancer and glioblastoma multiforme cell line models, we show that two alternatively spliced, functional truncated isoforms of p53 (p53β and p53γ, comprising exons 1 to 9β or 9γ, respectively) and that lack the C-terminal MDM2-binding domain have markedly reduced susceptibility to MDM2-mediated degradation but are highly susceptible to nonsense-mediated decay (NMD), a regulator of aberrant mRNA stability. In cancer cells harboring MDM2 overexpression or TP53 mutations downstream of exon 9, NMD inhibition markedly upregulates p53β and p53γ and restores activation of the p53 pathway. Consistent with p53 pathway activation, NMD inhibition induces tumor suppressive activities such as apoptosis, reduced cell viability, and enhanced tumor radiosensitivity, in a relatively p53-dependent manner. In addition, NMD inhibition also inhibits tumor growth in a MDM2-overexpressing xenograft tumor model. These results identify NMD inhibition as a novel therapeutic strategy for restoration of p53 function in p53-deficient tumors bearing MDM2 overexpression or p53 mutations downstream of exon 9, subgroups that comprise approximately 6% of all cancers.

A Novel Oncoprotein Pirh2: Rising from the Shadow of MDM2.

The E3 Ligase Ring1 Targets P53 For Degradation And Promotes Cancer Cell Proliferation And Survival

Pirh2 RING-finger E3 ubiquitin ligase: its role in tumorigenesis and cancer therapy.

Pirh2 RING‐finger E3 Ubiquitin Ligase: Its Role in Tumorigenesis and Cancer Therapy

Pirh2 and Tumor

Research Progress in Association Between the Ubiquitin Ligase Pirh2 and Malignant Tumors

Inhibition of Nonsense-Mediated Decay Rescues P53β/γ Isoform Expression and Activates the P53 Pathway in MDM2-overexpressing and Select P53-Mutant Cancers

Pirh2 mediates the sensitivity of myeloma cells to bortezomib via canonical NF-κB signaling pathway

PI3K/Akt/mTOR pathway inhibitors in cancer: a perspective on clinical progress.

The Regulation of MDM2 Oncogene and Its Impact on Human Cancers

Small Molecule Inhibitors of the P53-Mdm2

PIR promotes tumorigenesis of breast cancer by upregulating cell cycle activator E2F1

Escape, or Vanish: Control the Fate of p53 through MDM2-Mediated Ubiquitination.

Novel MDM2 p53-independent functions identified through RNA silencing technologies.

Phosphorylation of Pirh2 by Calmodulin-Dependent Kinase II Impairs Its Ability to Ubiquitinate P53.

The P73 Tumor Suppressor is Targeted by Pirh2 RING Finger E3 Ubiquitin Ligase for the Proteasome-dependent Degradation*

RPL23 Links Oncogenic RAS Signaling to P53-Mediated Tumor Suppression

190 Novel Classes of P53 Activators for Cancer Therapy

Residues 240-250 in the C-Terminus of the Pirh2 Protein Complement the Function of the Ring Domain in Self-Ubiquitination of the Pirh2 Protein

An Overview of PROTACs Targeting MDM2 as a Novel Approach for Cancer Therapy

Rbb, A Novel Transcription Repressor, Represses the Transcription of Hdm2 Oncogene